Genetic testing

Genomenon Partners with Pharming to Advance APDS Diagnosis

Retrieved on: 
Thursday, May 2, 2024
Mortality, American College, Probability, Laboratory, ANN, Survival, APDS, Disorder, Partnership, Genetic testing, PIK3R1, Molecular diagnostics, Disease, ACMG, Lymphoma, Patient, Bronchiectasis, AMP, Primary immunodeficiency, Caregiver, Genome, Immunodeficiency, Diagnosis, Infection, PIK3CD, Medicine, Activated, Medical genetics, Gene, Medical device

ANN ARBOR, Mich., May 2, 2024 /PRNewswire-PRWeb/ -- Genomenon, a genomic intelligence company, has partnered with Pharming Group in an effort to make variant data on the PIK3CD and PIK3R1 genes available to genetic testing labs, as well as clinicians and researchers, worldwide. This data enables accurate molecular diagnoses and supports the precise medical management of the disease. The partnership also improves the ability of diagnostic laboratories and clinicians to resolve variants of uncertain significance (VUSs) and advances Genomenon's mission to curate the human genome.

Key Points: 
  • APDS, or Activated PI3K delta syndrome, is a rare primary immunodeficiency affecting approximately 1 to 2 people per million worldwide.
  • As the symptoms of APDS can be associated with a variety of conditions, patients typically experience a median 7-year diagnostic delay.
  • "Through our AI-driven technology and genomic expertise, Genomenon has produced the world's most comprehensive variant landscape on PIK3CD and PIK3R1.
  • This curated genetic dataset is being made available to the community through Genomenon's Mastermind Genomic Intelligence Platform to help inform and accelerate the diagnosis for patients with APDS," said Mike Klein, Genomenon CEO.

Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering

Retrieved on: 
Monday, April 22, 2024
Sale, Prospectus, Ovarian cancer, Warrant, GTG, Regulation D, Health, 3rd Floor, ASX, Research, Genetic testing, Form, ADS, American depositary receipt, B2B, Security (finance)

MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, at an offering price of US$2.00 per ADS.

Key Points: 
  • The gross proceeds to the Company from this offering were approximately US$2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering of the ADSs (or ADS equivalents) in the registered direct offering were made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering were filed with the SEC.
  • Authorised for release by the Board of Directors of Genetic Technologies Limited.

Genetic Technologies Announces $2 Million Registered Direct Offering

Retrieved on: 
Thursday, April 18, 2024
Sale, Prospectus, Ovarian cancer, Warrant, GTG, Regulation D, Health, 3rd Floor, ASX, Research, Genetic testing, Form, ADS, American depositary receipt, B2B, Security (finance)

The closing of the offering is expected to occur on or about April 22, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about April 22, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from this offering are expected to be approximately $2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering of the ADSs (or ADS equivalents) in the registered direct offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC.

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

Retrieved on: 
Wednesday, April 17, 2024
Myriad Genetics, MYGN, Depression, Life, Genetic testing, Mental health, Patient, Medicine, Anxiety, Nursing

When able to attend important events, 71% of the respondents say their mental health has kept them from being fully present. Nearly eight in 10 respondents (78%) said poor mental health prevented them from “having fun/enjoying myself” in the past year -- a number that jumps to 82% for those diagnosed with anxiety and/or depression.

Key Points: 
  • SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health.
  • Of those diagnosed with anxiety and/or depression, half (50%) said they have lost years of their lifetime because of poor mental health – and 12% said they’ve lost decades.
  • When able to attend important events, 71% of the respondents say their mental health has kept them from being fully present.
  • “I had to call off my wedding to focus on my mental health,” said Courtney Nugent, a GeneSight patient based in Massachusetts.

GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year

Retrieved on: 
Tuesday, April 16, 2024
Education, Breast cancer, Patient, Cancer, GTG, Global Reach, Comfort, Mammography, Risk, Woman, Breast MRI, Health, ASX, Research, Genetic testing, Growth, Disease, General practice, Gynaecology, Pharmaceutical industry

The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.

Key Points: 
  • The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.
  • Clinicians embracing and offering geneType to patients have tended to be:
    Focussed on offering patients the best available care; and
    Comfortable with explaining results to patients.
  • Clinical adoption of geneType is now in more than 12 US States, Canada and nationally in Australia.
  • “Our success in expanding clinician adoption and growth in sales reflects the growing recognition of the transformative potential of personalized medicine,” remarked Simon Morriss, CEO of GENE.

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

Retrieved on: 
Tuesday, April 16, 2024
Patient, DiGeorge syndrome, American College, MYGN, Pregnancy, Test management, Myriad Genetics, Ventricular septal defect, FACMG, MD, Doctor of Philosophy, Genetic testing, Medical genetics, Genetics, DNA, SNP, PPV, Genomics, Medicine, FACOG, Dietary supplement

“This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.

Key Points: 
  • “This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.
  • This study enables greater confidence for providers when they receive positive screening results for 22q11.2 microdeletion.
  • 22q11.2 deletion syndrome (22q11.2DS), often called DiGeorge syndrome, is caused by deletions on chromosome 22 (22q11.2 microdeletions).
  • The American College of Medical Genetics and Genomics recently recommended that 22q11.2DS screening be offered to all pregnant patients.

Natera to Report its First Quarter 2024 Results on May 9

Retrieved on: 
Wednesday, May 1, 2024
Oncology, Health, Genetics, General Health, Pharmaceutical, Biotechnology, DNA, NTRA, Webcast, Genetic testing

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024.
  • Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m.
  • ET).

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

Retrieved on: 
Wednesday, May 1, 2024
Health, Consumer, Women, Genetics, Baby, Maternity, Clinical Trials, Biotechnology, Fetus, Nucleic acid thermodynamics, Gamma globulin, Episcopal conference, American College, NTRA, Laboratory, RHD (gene), Anemia, Risk, Pregnancy, Blood, Northwell Health, Quality, Genetic testing, Obstetrics, DNA, SNP, ACOG, ASHG, NIPT, Patient, Human genetics, Society, Physician, Antibody, Panorama, Dietary supplement

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.
  • This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg).
  • Natera’s test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including complex pseudogene and RhD-CE-D hybrid variants.
  • The vast majority of other NIPT laboratories do not offer fetal RhD assessment, which makes it a key differentiator in addition to Natera’s core SNP-based technology.

TeleRare Health™ Announces Launch of National Virtual Clinic for Rare Disease Patients

Retrieved on: 
Tuesday, April 30, 2024
Wilson's disease, Bangladesh Technical Education Board, Genomics, Kidney, SCID, Diagnosis, Safety, NIH, AI, Heart, Adrenoleukodystrophy, MD, Partnership, Children's National Hospital, DMD, FXS, Research, Human, Genetic testing, Disease, Patient, ALD, Pediatrics, Krabbe disease, Duchenne muscular dystrophy, PD, GMG, Fragile X syndrome, Pharmaceutical industry

MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- 8:00a (CET) April 30, 2024 - TeleRare Health™ launched today, a virtual clinic for Rare Disease patients and their families.

Key Points: 
  • MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- 8:00a (CET) April 30, 2024 - TeleRare Health™ launched today, a virtual clinic for Rare Disease patients and their families.
  • TeleRare Health aims to be the premier provider of virtual care for rare and genomic disease nationwide, envisioning a world where all patients have access to cutting edge diagnostics, treatments, and specialists.
  • "Significant breakthroughs have occurred in the management of rare disease," said Alex Katz, MD, medical geneticist and Chief Medical Officer of TeleRare Health.
  • We're overdue for a virtual clinic for the millions of Americans with rare disease conditions, and TeleRare Health's launch is cause for optimism.

Oncology Precision Medicine Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 26, 2024
Pharmaceutical, Health, Oncology, Molecule, USD, Mortality, Radiation, Volunteering, Administration, Breast cancer, Cancer, Lung cancer, World Health Organization, Hub, Risk, Immunotherapy, Research, Genetic testing, Obesity, Disease, DNA, Therapy, Oncogene, Patient, Gastrointestinal cancer, Bone marrow, MD Anderson Cancer Center, Clinical trial, Medicine, Viral, Type, Interest, Mayo Clinic Cancer Center, Growth, Prevalence, Medical imaging

The growth in the oncology precision medicine market size over the next decade is likely to be the result of an anticipated increase in patient population and rise in the demand for personalized medicine in oncology for precision cancer care.

Key Points: 
  • The growth in the oncology precision medicine market size over the next decade is likely to be the result of an anticipated increase in patient population and rise in the demand for personalized medicine in oncology for precision cancer care.
  • Regional Analysis: North America Emerged as the Hub of Oncology Precision Medicine; Europe to be the Fastest Growing Market
    In 2024, North America is anticipated to capture close to 42% market share of the overall oncology precision medicine market.
  • In recent years, demand for oncology precision medicine has witnessed a tremendous increase in North America.
  • The oncology precision medicine market report presents an in-depth analysis of various precision medicine oncology companies in this domain, across different segments, as defined below: